19.84 -0.27 (-1.34%)
Pre-Market: 9:03AM EDT
|Bid||19.85 x 3000|
|Ask||19.89 x 2200|
|Day's Range||20.10 - 20.23|
|52 Week Range||17.42 - 23.03|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||33.54|
|Forward Dividend & Yield||0.35 (1.73%)|
|1y Target Est||N/A|
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.
The following is a roundup of the top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.
After the FDA warned about "young blood" purporting to treat a range of diseases, including Alzheimer's and post-traumatic stress disorder, a company with a clinical operation in San Francisco has ceased its treatments.
Over 28 years, the company spent a half-billion dollars on developing inhaled lung-disease drugs that fell short of FDA approval.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Dividends play an important role in compounding Read More...
Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...